The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2022 | Overview on the use of KRd for myeloma in a real-world setting
In this video, Sally Moore, MD, Royal United Hospital, Bath, UK, discusses some updates on the use of carfilzomib, lenalidomide and dexamethasone (KRd) in patients with multiple myeloma at first relapse in a real-world setting. Dr Moore gives an overview on the efficacy of this regimen, including prolonged progression-free survival (PFS) and deepening of responses, as well as the toxicities associated with KRd treatment. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
